The decision follows the pilot study jointly conducted by Lumito and Truly Labs earlier this year. The results, communicated in Lumito’s press release on 28 August 2025, demonstrated that the SCIZYS platform can generate more information from each tissue sample and enable more precise analyses compared to traditional methods.

After completing its evaluation, Truly Labs concluded that SCIZYS adds significant value — both by improving the quality of existing analyses and by enabling new types of studies.

“We see that Lumito’s SCIZYS platform strengthens our ability to deliver even more detailed and reliable results to our customers. The combination of high sensitivity, precise localisation, and wide dynamic range provides us with new tools to deepen our understanding of biological processes and further enhance our analyses,” commented Karin von Wachenfeldt, CEO of Truly Labs.

Lumito’s SCIZYS platform is based on the Company’s unique use of upconverted nanoparticles (UCNPs) as a light source, which eliminates background interference and enables high-contrast imaging with exceptional detail.

“We are very pleased that Truly Labs has chosen to integrate Lumito’s technology into its offering. This confirms the relevance and potential of our technology to create concrete value in research environments where data quality and precision are key,” commented Sanna Wallenborg, CEO of Lumito.

The collaboration between Lumito and Truly Labs, which began in December 2024, has developed step by step, and Truly Labs’ decision to integrate the technology into its customer offering marks an important milestone in Lumito’s strategy to establish SCIZYS as a valuable platform within preclinical research and drug development.